Key points
- Bremelanotide has Phase 3 human data and FDA approval for a specific HSDD indication.
- The approved route of administration is subcutaneous injection; “PT-141” products with uncertain contents sold online do not have the same quality assurance as the licensed product.
- An HSDD diagnosis is not based solely on a low level of libido; the complaint must cause significant distress and must not be better explained by other causes.
- Nausea, flushing, headache, injection reactions, and a temporary increase in blood pressure may occur.
- It should not be used in patients with uncontrolled hypertension or known cardiovascular disease.
What is bremelanotide?
Bremelanotide is a synthetic peptide that affects central melanocortin receptors. Unlike hormone replacement, it aims to modulate central nervous system pathways associated with sexual desire.
For what condition is it approved?
FDA approval is for acquired, generalized HSDD that develops in premenopausal women who previously had no problems with sexual desire and occurs regardless of the situation or partner. The low desire must not be better explained by an existing medical/psychiatric illness, relationship problem, or medication/substance effect. The treatment is not approved to enhance sexual performance.
What does the research show?
Phase 3 studies have reported significant improvements in measures of sexual desire and distress related to low desire in premenopausal women with a qualifying HSDD diagnosis. The clinical benefit may vary from person to person; therefore, treatment response is assessed not only by the frequency of sexual activity but also by changes in the person’s level of desire and associated distress.
How is it administered?
The approved product is used subcutaneously. The product label includes as-needed use, spacing between doses, and limits on monthly frequency of use. IV bremelanotide/PT-141 is not an approved or standard clinical practice.
In whom should other causes be investigated first?
Depression, anxiety, relationship problems, chronic stress, sleep disorders, pain, menopause, thyroid disorders, testosterone/estrogen changes, and medications such as SSRIs may play a role in low libido. Therefore, the biopsychosocial causes of low desire should be evaluated before making a treatment decision.
Safety and precautions
The most commonly reported side effects include nausea, flushing, headache, and injection site reactions. A temporary increase in blood pressure and a change in heart rate may occur. It should not be used in patients with uncontrolled hypertension or known cardiovascular disease. Focal hyperpigmentation may develop in some individuals, and this change may not always be completely reversible.
Use in men
Male sexual dysfunction is not an approved indication for bremelanotide. When evaluating libido or erectile dysfunction in men, testosterone, vascular health, metabolic risk, medications, sleep, and psychological/relationship factors should be addressed separately. The erectile dysfunction and low testosterone guides explain this distinction.
Our approach at our Bodrum clinic
When evaluating bremelanotide, we first review the HSDD diagnostic criteria and other causes of low desire. Medications, menopausal status, mental health, relationship factors, cardiovascular risk, and the person’s expectations of treatment are evaluated together. We do not place the approved medication in the same category as products with uncertain standardization sold online under the name “PT-141.”
Frequently asked questions
Does PT-141 increase libido in women?
Bremelanotide is approved for premenopausal women who meet the criteria for a specific HSDD diagnosis and has shown improvement in measures of distress associated with sexual desire in clinical studies. Not every presentation of low libido is the same diagnosis.
Can it be used after menopause?
The FDA-approved indication is acquired, generalized HSDD in premenopausal women. Low desire and genitourinary complaints after menopause require a different evaluation.
Is PT-141 administered IV?
The approved route of administration is subcutaneous. IV administration is not a licensed standard protocol.
Related content
- Sexual Health and Healthy Aging
- Low Libido and Lack of Sexual Desire
- Erectile Dysfunction
- Main Guide to Peptide Treatments
References
- U.S. FDA. Vyleesi (bremelanotide) NDA 210557 approval and prescribing information.
- Kingsberg SA, et al. RECONNECT phase 3 studies of bremelanotide for HSDD. PMID: 31599840.
Written and medically reviewed by: Dr. Kerem Çağlayan
Last medical review: 10 September 2026
Disclaimer: This content is intended for general medical information; it is not a substitute for individual diagnosis or treatment recommendations.
